Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most discontinuation/abrupt-stop symptom claims (insomnia, nausea, headache, anxiety) and the general recommendation to taper are supported by the label. However, several listed withdrawal symptom types are not supported in the provided label excerpts, and some claims (seizures as part of withdrawal; seizures risk especially for epilepsy; weight-change nuances and mechanisms after stopping) are not supported by the provided text.
Category Scores
Accurate Statements
Stopping pregabalin suddenly can cause withdrawal effects.
Label 5.6 (Risks Associated with Abrupt or Rapid Discontinuation): reports of symptoms after abrupt/rapid discontinuation; taper gradually over minimum of 1 week rather than discontinuing abruptly.
After stopping pregabalin, withdrawal-type symptoms may occur.
Label 5.6: some patients reported symptoms following abrupt or rapid discontinuation; label recommends taper.
Rebound of the original condition (e.g., pain or anxiety symptoms returning) can occur after discontinuing pregabalin.
No direct label excerpt provided about rebound of the original condition after discontinuation; not verifiable from provided excerpts.
Abrupt stopping of pregabalin can be risky for some patients.
Label 5.6: taper gradually rather than discontinuing abruptly due to reported symptoms.
Stopping pregabalin without a taper can cause withdrawal symptoms.
Label 5.6: taper gradually over a minimum of 1 week rather than discontinuing abruptly; reported symptoms include insomnia, nausea, headache, anxiety.
Clinicians usually recommend tapering pregabalin gradually rather than stopping all at once.
Label 5.6: taper gradually over a minimum of 1 week rather than discontinuing abruptly.
Withdrawal symptoms from stopping pregabalin can include trouble sleeping.
Label 5.6: insomnia reported after abrupt/rapid discontinuation.
Withdrawal symptoms from stopping pregabalin can include anxiety.
Label 5.6: anxiety reported after abrupt/rapid discontinuation.
Withdrawal symptoms from stopping pregabalin can include nausea.
Label 5.6: nausea reported after abrupt/rapid discontinuation.
Withdrawal symptoms from stopping pregabalin can include headache.
Label 5.6: headache reported after abrupt/rapid discontinuation.
Urgent medical care is needed if seizures occur during or after stopping pregabalin.
No label excerpt provided addressing seizures in the context of discontinuation or withdrawal; not supported by provided text.
Unsupported Statements
Rebound of the original condition (e.g., pain or anxiety symptoms returning) can occur after discontinuing pregabalin.
Provided label excerpts do not mention symptom rebound/return after discontinuation.
Withdrawal symptoms from stopping pregabalin can include irritability.
Label 5.6 provided list includes insomnia, nausea, headache, anxiety, and diarrhea; irritability not listed in provided excerpts.
Withdrawal symptoms from stopping pregabalin can include sweating.
Sweating/diaphoresis not listed among abrupt discontinuation symptoms in provided label excerpts.
Stopping pregabalin can cause seizures in some cases.
No provided label excerpt links abrupt discontinuation of pregabalin extended-release tablets to seizures.
Seizures risk is especially relevant in people who take pregabalin for epilepsy-related conditions.
No provided label excerpt addresses seizures risk in relation to discontinuation and epilepsy indication.
Many pregabalin withdrawal symptoms show up within days of stopping.
Provided label excerpts do not specify timing (e.g., within days) for discontinuation symptoms.
Some pregabalin withdrawal symptoms can last longer in some people.
Provided label excerpts do not state duration variability of discontinuation symptoms.
Weight changes after stopping pregabalin depend on what drove the weight gain.
Provided label excerpts discuss weight gain as a treatment effect, not weight-change drivers or post-stopping dependence.
Pregabalin-related weight gain may be due to increased appetite while on pregabalin.
Label excerpt 5.8 states weight gain may occur but does not attribute to appetite.
Pregabalin-related weight gain may be due to reduced activity during treatment from sedation or fatigue.
Label excerpt 5.8 does not attribute to activity reduction; while dizziness/somnolence are mentioned, no causal mechanism for weight gain is provided.
Pregabalin-associated weight gain may involve fluid retention that can fluctuate.
Label discusses peripheral edema and weight gain during treatment but does not describe fluctuating fluid retention after stopping.
After stopping pregabalin, return of symptoms (pain/anxiety) can reduce or increase activity and appetite.
No provided label excerpt discusses post-discontinuation return of symptoms or appetite/activity effects.
Some people gradually lose weight after they stop pregabalin as appetite and energy normalize.
No provided label excerpt addresses weight loss patterns after discontinuation.
Some people see little change or weight fluctuates after stopping pregabalin.
No provided label excerpt addresses post-stopping weight trajectories.
The usual approach to discontinuing pregabalin is a gradual taper planned with a prescriber.
Label 5.6 supports tapering gradually; however, 'with a prescriber' is not explicitly stated in provided excerpts.
Taper schedule depends on current dose, how long pregabalin was used, and why it is taken.
Provided label excerpt specifies a minimum of 1 week taper but does not state that taper schedule depends on dose/duration/indication.
Urgent medical care is needed if severe agitation, confusion, or hallucinations occur during or after stopping pregabalin.
Provided label excerpts do not list agitation/confusion/hallucinations as discontinuation symptoms or specify urgent care triggers for these in this context.
Urgent medical care is needed if breathing problems occur during or after stopping pregabalin.
Label 5.4 addresses respiratory depression risk with CNS depressants/underlying respiratory impairment and monitoring; it does not specifically tie breathing problems to stopping pregabalin or state an 'urgent medical care' threshold for discontinuation.
Urgent medical care is needed if signs of a serious allergic reaction occur (swelling of face/lips, trouble breathing) during or after stopping pregabalin.
Label excerpts support angioedema/hypersensitivity and discontinuation/seek care; however, they are not explicitly framed as 'during or after stopping pregabalin.' (Still generally directionally consistent for serious allergic reaction symptoms, but 'during or after stopping' context is not supported.)
Pregabalin can cause weight gain in some people during treatment.
This statement is supported as a treatment effect by label 5.8, but as written it's broadly true; however included here only if overall list requires strict label linkage. If treated as a claim about during treatment, it is supported by label 5.8.
Withdrawal-type symptoms may occur after discontinuing pregabalin.
Generally supported for abrupt/rapid discontinuation (5.6), but the claim is phrased broadly without the abrupt/rapid qualifier; the label specifically addresses abrupt/rapid discontinuation.
Many pregabalin withdrawal symptoms show up within days of stopping.
Timing not provided in label excerpt 5.6.
Some pregabalin withdrawal symptoms can last longer in some people.
Duration not provided in label excerpt 5.6.
Contradictions
Low
AI Statement
Weight changes after stopping pregabalin depend on what drove the weight gain.
Label Reference
No contradiction; label does not address this, so not a direct conflict.
Important Omissions
Specific label-listed discontinuation symptoms after abrupt/rapid discontinuation include diarrhea (and insomnia, nausea, headache, anxiety). The AI list did not explicitly include diarrhea.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several withdrawal symptom claims (e.g., seizures, irritability, sweating) are not supported by the provided label excerpts, which could mislead. The label does support tapering and lists certain symptoms (insomnia, nausea, headache, anxiety, diarrhea).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims about withdrawal manifestations (especially seizures; irritability/sweating) and post-discontinuation course (timing/duration, rebound, weight after stopping) are not supported by the provided label excerpts.
Suggested Improvement
Limit discontinuation/withdrawal discussion to the label-supported concept of abrupt/rapid discontinuation risk and the specifically listed symptoms (insomnia, nausea, headache, anxiety, diarrhea) and to the label-supported taper instruction (gradually over minimum 1 week). Remove or rephrase unsupported symptom types and post-stopping weight/mechanism assertions unless supported by additional label sections.